GeneDx Q4 revenue $58.1M (+27% YoY); exome/genome revenue up 68%; guides FY2024 $220-230M

GeneDx Holdings Corp.

2023-FY EPS reported -$7.23 revenue$202,566,000

Q4 revenue from continuing ops $58.1M (+27% YoY); exome/genome revenue $39.2M (+68% YoY).
Adjusted gross margin expanded to 56% (from 41% Q4 2022); exome/genome margin >60%.
Adjusted net loss narrowed to $17.8M, a 76% improvement YoY; cash burn reduced 51% YoY.
FY2024 revenue guidance $220-230M; reiterates path to profitability in 2025.
Exome/genome test volume 15,663 in Q4 (+99% YoY); 49,439 full year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeneDx Holdings Corp. reported the fourth quarter and full year of 2023 results: revenue $58.1 million, net income $17.8 million. Guidance initiated.

Period: the fourth quarter and full year of 2023
Revenue: $58.1 million
Net income: $17.8 million
Guidance: initiated
Result: reported results

Exact text from the filing

reach profitability in 2025.” Fourth Quarter and Full Year 2023 Financial Results (Unaudited) 1,2,3 Revenues Fourth quarter 2023: • Revenues from continuing operations grew to $58.1 million, an increase of 27% year-over-year and 15% sequentially. ◦ Total company revenues were $57.4 million. • Exome and genome test revenue grew to $39.2 million, an increase of 68%

View on SEC.gov

Browse all earnings releases →

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.